CN105343096B - Wnt信号通路抑制剂的新用途 - Google Patents
Wnt信号通路抑制剂的新用途 Download PDFInfo
- Publication number
- CN105343096B CN105343096B CN201410409530.1A CN201410409530A CN105343096B CN 105343096 B CN105343096 B CN 105343096B CN 201410409530 A CN201410409530 A CN 201410409530A CN 105343096 B CN105343096 B CN 105343096B
- Authority
- CN
- China
- Prior art keywords
- mouse
- pkd2
- cre
- vil
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 14
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims abstract description 48
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims abstract description 48
- 210000003734 kidney Anatomy 0.000 claims abstract description 44
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940109239 creatinine Drugs 0.000 claims abstract description 18
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 208000026292 Cystic Kidney disease Diseases 0.000 claims abstract description 11
- 206010038423 Renal cyst Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 5
- 208000024891 symptom Diseases 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 5
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 58
- 101100029891 Caenorhabditis elegans pkd-2 gene Proteins 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000016362 Catenins Human genes 0.000 description 2
- 108010067316 Catenins Proteins 0.000 description 2
- 102100032917 E3 SUMO-protein ligase CBX4 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000641959 Homo sapiens Villin-1 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 101710129670 Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 description 2
- 108010017601 Tankyrases Proteins 0.000 description 2
- 102000054384 Villin-1 Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000037416 cystogenesis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 241000445129 Eremomyces bilateralis Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010019646 Hepatic cyst Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 description 1
- 101710129674 Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 101150029220 Tprg1l gene Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000028284 monogenic inheritance Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001042 thoracic artery Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种Wnt信号通路抑制剂的新用途。本发明所提供的Wnt信号通路抑制剂的新用途具体为Wnt信号通路抑制剂在制备治疗常染色体显性遗传性多囊肾(ADPKD)的产品中的应用;所述Wnt信号通路抑制剂具体为XAV939。本发明以Vil‑Cre:Pkd2f3/f3小鼠作为ADPKD动物模型,结果表明Wnt信号通路抑制剂—XAV939可减弱Vil‑Cre:Pkd2f3/f3小鼠的肾囊肿程度,可降低Vil‑Cre:Pkd2f3/f3小鼠的肾脏体重比,可降低Vil‑Cre:Pkd2f3/f3小鼠的肾脏囊肿指数,可降低Vil‑Cre:Pkd2f3/f3小鼠的血液中肌酐和尿素氮的含量。本发明对于ADPKD发病机制的分析,对于治疗ADPKD的药物的研发均具有重要意义。
Description
技术领域
本发明属于生物医药领域,涉及Wnt信号通路抑制剂的新用途,特别涉及Wnt信号通路抑制剂—XAV939在治疗常染色体显性遗传性多囊肾中的应用。
背景技术
XAV939是小分子选择性抑制剂,可以抑制Wnt通路转录因子β-catenin调节的转录。XAV939通过抑制端锚聚合酶1、2(Tankyrase 1 and Tankyrase 2),使二者不能与Axin高保守区相互作用,进而阻止了Axin被泛素途径降解。由于XAV939能够稳定β-catenin降解复合体中的组成成分Axin,延长其半衰期,使Axin的浓度上升,从而促使细胞内的β-catenin降解加速,进而抑制经典Wnt通路的活性。XAV939作用于端锚聚合酶1和端锚聚合酶1时IC50分别为11nM和4nM。
目前,该药已用于临床I期实验。
常染色体显性遗传性多囊肾(Autosomal Dominant Polycystic KidneyDisease,ADPKD)疾病是最常见的单基因遗传性肾病之一。其主要临床症状为双侧肾脏形成大量大小不等的球形液性囊肿,并进行性增大,破坏肾脏的结构和功能,最终导致肾功能衰竭。ADPKD通常在成人中发病,其发病率为1:400-1000,是目前世界上终末肾衰竭的第三大病因。除肾病表型外,ADPKD患者的非肾脏部位病变表型也十分明显:83%的ADPKD患者出现肝囊肿,16%的患者出现脑动脉瘤。其他病理表型包括主动脉根,胸部动脉异常,二尖瓣脱垂以及腹壁疝气。约50%的患者年满60岁后将出现终末肾衰竭。正常人的尿素氮(BUN)参考范围为2.14-7.14mmol/L,血肌酐(CRE)参考范围为44-133μmol/L,当血肌酐超过133μmol/L为炎症损伤期,超过186μmol/L为肾功能损伤期,超过451umol/L为肾功能衰竭期。
发明内容
本发明的目的是提供Wnt信号通路抑制剂的新用途。
本发明所提供的Wnt信号通路抑制剂的新用途,可为Wnt信号通路抑制剂在制备治疗常染色体显性遗传性多囊肾(ADPKD)的产品中的应用。
进一步,Wnt信号通路抑制剂在制备如下任一产品中的应用也属于本发明的保护范围:
(1)减弱患病机体肾囊肿程度的产品;
(2)降低患病机体肾脏体重比的产品;
(3)降低患病机体的肾脏囊肿指数的产品;
(4)降低患病机体血液中肌酐和/或尿素氮含量的产品。
在本发明中,所述Wnt信号通路抑制剂具体为XAV939(化学式:C14H11F3N2OS)。
所述患病机体为具有常染色体显性遗传性多囊肾(ADPKD)临床症状的机体,如常染色体显性遗传性多囊肾(ADPKD)患者。在本发明中,以Vil-Cre:Pkd2f3/f3小鼠作为ADPKD动物模型,即为具有常染色体显性遗传性多囊肾(ADPKD)临床症状的机体,上述(1)则具体表现为减弱Vil-Cre:Pkd2f3/f3小鼠的肾囊肿程度;上述(2)则具体表现为降低Vil-Cre:Pkd2f3 /f3小鼠的肾脏体重比;上述(3)则具体表现为降低Vil-Cre:Pkd2f3/f3小鼠的肾脏囊肿指数;上述(4)则具体表现为降低Vil-Cre:Pkd2f3/f3小鼠血液中的肌酐和/或尿素氮含量。
本发明的再一个目的是提供一种产品。
本发明所提供的产品的活性成分为Wnt信号通路抑制剂,该产品具有如下用途中的至少一种:
(a)治疗常染色体显性遗传性多囊肾;
(b)减弱患病机体肾囊肿程度;
(c)降低患病机体肾脏体重比;
(d)降低患病机体的肾脏囊肿指数;
(e)降低患病机体血液中肌酐和/或尿素氮含量。
在本发明中,所述Wnt信号通路抑制剂具体为XAV939(化学式:C14H11F3N2OS)。
所述患病机体为具有常染色体显性遗传性多囊肾(ADPKD)临床症状的机体,如常染色体显性遗传性多囊肾(ADPKD)患者。在本发明中,以Vil-Cre:Pkd2f3/f3小鼠作为ADPKD动物模型,即为具有常染色体显性遗传性多囊肾(ADPKD)临床症状的机体,上述(b)则具体表现为减弱Vil-Cre:Pkd2f3/f3小鼠的肾囊肿程度;上述(c)则具体表现为降低Vil-Cre:Pkd2f3 /f3小鼠的肾脏体重比;上述(d)则具体表现为降低Vil-Cre:Pkd2f3/f3小鼠的肾脏囊肿指数;上述(e)则具体表现为降低Vil-Cre:Pkd2f3/f3小鼠血液中的肌酐和/或尿素氮含量。
在以上所述的各应用或产品中,所述产品具体可为药物。
以上所有的所述Vil-Cre:Pkd2f3/f3小鼠均按照包括如下步骤的方法构建得到:
(I)将Pkd2f3/f3小鼠(记载于“lngyu Kim,Tianbing Ding,Yulong Fu,etal.Conditional Mutation of Pkd2 Causes Cystogenesis and Upregulatesβ-Catenin.J Am Soc Nephrol,2009(20):2556-2569”一文)与带有Vil-Cre重组酶的转基因小鼠(购自The Jackson Laboratory,Strain Name:B6.SJL-Tg(Vil-cre)997Gum/J,StockNumber:004586,详见网址:http://jaxmice.jax.org/strain/004586.html)进行杂交,得到F1代(其中理论上有1/2后代的基因型为Vil-Cre:Pkd2+/f3;1/2后代的基因型为Pkd2+/f3);
(II)将步骤(I)得到的F1代(Vil-Cre:Pkd2+/f3)与所述Pkd2f3/f3小鼠进行回交,得到回交后代;
(III)从步骤(II)得到的回交后代中筛选出Pkd2基因纯合,同时表达Vil-Cre的小鼠,即为Vil-Cre:Pkd2f3/f3小鼠。
其中,步骤(III)中所述“从步骤(II)得到的回交后代中筛选出Pkd2基因纯合,同时表达Vil-Cre的小鼠”,可按照如下方法实现:以所述回交后代的小鼠基因组为模板,采用针对Pkd2基因的引物(三条:5’-TCT GAC TTG CAG ACT GTG GG-3’,5’-AGG TAG GGG AAGGTC AGG GTT GG-3’,5'-TTTACGTCCAGCCAAGCT-3')和针对Cre基因的引物(两条:5’-CCAGGT TAC GGA TAT AGT TCA TG-3’,5’-TGC CAC GAC CAA GTG ACA GC-3’)分别进行PCR扩增;针对Pkd2基因进行PCR扩增得到大小为650bp的单一条带(Pkd2基因纯合),同时针对Cre基因进行PCR扩增得到大小为650bp的条带(表达Vil-Cre)的小鼠即为所述Vil-Cre:Pkd2f3 /f3小鼠。
本发明以Vil-Cre:Pkd2f3/f3小鼠作为ADPKD动物模型,进行了Wnt信号通路抑制剂—XAV939对常染色体显性遗传性多囊肾(ADPKD)治疗的效果研究,结果表明,Wnt信号通路抑制剂—XAV939对于治疗常染色体显性遗传性多囊肾具有一定的效果,具体体现在:(1)可减弱Vil-Cre:Pkd2f3/f3小鼠的肾囊肿程度;(2)可降低Vil-Cre:Pkd2f3/f3小鼠的肾脏体重比;(3)可降低Vil-Cre:Pkd2f3/f3小鼠的血液中肌酐和/或尿素氮的含量。本发明对于常染色体显性遗传性多囊肾(ADPKD)发病机制的分析,对于治疗常染色体显性遗传性多囊肾(ADPKD)的药物的研发均具有重要意义。
附图说明
图1为回交后代小鼠基因型的PCR检测结果。其中,A为针对Pkd2基因PCR检测结果,Pkd2f3/f3为Pkd2基因纯合,Pkd2+/f3为Pkd2基因杂合;B为针对Cre基因的PCR检测结果,Vil-cre为表达Vil-Cre;WT为不表达Vil-Cre。
图2为Vil-Cre:Pkd2f3/f3小鼠模拟人类ADPKD的疾病表型。其中,A为Vil-Cre:Pkd2f3/f3小鼠肾脏形态;B为Vil-Cre:Pkd2f3/f3小鼠肝脏形态;C为Vil-Cre:Pkd2f3/f3小鼠胰腺形态;D为Vil-Cre:Pkd2f3/f3小鼠的肾脏横切面;E为Pkd2f3/f3小鼠的肾脏横切面。
图3为两组小鼠的肾脏HE染色结果。其中,A表示治疗组;B表示对照组。A和B中,1、2、3、4均表示两组不同个体小鼠的肾脏HE染色结果。
图4为两组小鼠的肾脏体重比测定结果。
图5为两组小鼠的肾脏囊肿指数测定结果。
图6为两组小鼠的血液中尿素氮(BUN)与肌酐(CRE)的含量测定结果。其中,A表示肌酐含量;B表示尿素氮含量。
具体实施方式
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
Pkd2f3/f3小鼠:记载于“lngyu Kim,Tianbing Ding,Yulong Fu,etal.Conditional Mutation of Pkd2 Causes Cystogenesis and Upregulatesβ-Catenin.J Am Soc Nephrol,2009(20):2556-2569”一文中。其构建及鉴定过程大体如下:首先,在Pkd2基因的3号外显子两侧插入两个loxP位点,在阳性选择性Neo的两侧有FRT位点,由于该结构没有完全阻断正常Pkd2基因的表达,所以用这种载体通过基因打靶技术产生的Pkd2nf3小鼠可避免死于胚胎期。再将Pkd2nf3小鼠与ACTB-Flep小鼠杂交,即产生没有Neo元件的Pkd2f3/f3小鼠。鉴于在Pkd2f3/f3小鼠中没有观察到多囊表型,PC2的表达也没有发生改变,认为这种Pkd2f3等位基因不会导致Pkd2的表达失活。
带有Vil-Cre重组酶的转基因小鼠:购自The Jackson Laboratory,Strain Name:B6.SJL-Tg(Vil-cre)997Gum/J,Stock Number:004586,详见网址:http://jaxmice.jax.org/strain/004586.html。
XAV939:Selleck公司,产品目录号S1180。分子量:312.31;化学式:C14H11F3N2OS;CAS号:284028-89-3;溶解性(25℃):DMSO 12mg/mL,水<1mg/mL,乙醇<1mg/mL;稳定性:3年-20℃粉状,6月-80℃溶于DMSO。
实施例1、Vil-Cre:Pkd2f3/f3小鼠模型的构建及鉴定
Vil-Cre:Pkd2f3/f3小鼠是利用Cre-loxP系统建立的可以条件性敲除Pkd2的小鼠模型,可产生与人类常染色体显性遗传性多囊肾(Autosomal Dominant Polycystic KidneyDisease,ADPKD)类似临床表型,并早期死于肾衰竭,可作为ADPKD动物模型。其构建及鉴定过程如下:
一、Vil-Cre:Pkd2f3/f3小鼠模型的构建
将Pkd2f3/f3小鼠与带有Vil-Cre重组酶的转基因小鼠(B6.SJL-Tg(Vil-cre)997Gum/J)进行杂交,得到F1代(理论上有1/2后代的基因型为Vil-Cre:Pkd2+/f3;1/2后代的基因型为Pkd2+/f3);将F1代中Vil-Cre:Pkd2+/f3小鼠(针对Cre基因进行PCR鉴定,具体方法参见下文,经鉴定得到大小为650bp目的条带的F1代小鼠)与Pkd2f3/f3小鼠进行回交,得到回交后代。
从以上所得回交后代中,筛选得到Pkd2基因纯合,同时可表达Vil-Cre的小鼠,具体操作如下:
提取回交后代鼠尾基因组,以其为模板,分别对Pkd2基因以及Cre基因进行PCR鉴定,其中针对Pkd2基因的PCR所用引物序列为如下三条:5’-TCT GAC TTG CAG ACT GTG GG-3’,5’-AGG TAG GGG AAG GTC AGG GTT GG-3’,5'-TTTACGTCCAGCCAAGCT-3';针对Cre基因的PCR所用引物序列为如下两条:5’-CCA GGT TAC GGA TAT AGT TCA TG-3’,5’-TGC CACGAC CAA GTG ACA GC-3’。当采用针对Pkd2基因的三条引物在同一反应体系中进行PCR扩增时,如果得到大小分别为650bp和350bp的两个条带,则对应的回交后代小鼠为Pkd2基因杂合(Pkd2+/f3),如果得到大小为650bp的单一条带,则对应的回交后代小鼠为Pkd2基因纯合(Pkd2f3/f3);当采用针对Cre基因的两条引物进行PCR扩增时,如果得到大小为650bp的目的条带,则对应的回交后代小鼠表达Vil-Cre,如果没有得到大小为650bp的目的条带,则对应的回交后代小鼠不表达Vil-Cre。
结果如图1所示,图1中A中的Pkd2f3/f3为Pkd2基因纯合,图1中B中的Vil-Cre为可表达Vil-Cre。经过以上鉴定,从回交后代中得到的Pkd2基因纯合,同时可表达Vil-Cre的小鼠,即为Vil-Cre:Pkd2f3/f3小鼠。Vil-Cre为受控于Villin1启动子的Cre酶,其中villin1启动子表达于小鼠胚胎期第12.5天的肠上皮细胞,小鼠在Cre酶的作用下,可在细胞水平上产生Pkd2d3/d3,由于Pkd2d3/d3等位基因上的3号外显子已被剪切掉,进而产生移码突变,导致3号外显子下游不远处产生终止子,进而使Pkd2基因产物PC2成为截断蛋白。
二、Vil-Cre:Pkd2f3/f3小鼠模型的鉴定
常规饲养步骤一得到的Vil-Cre:Pkd2f3/f3小鼠,观察其存活状态。待小鼠四月龄,取其肾脏、肝脏、胰腺,观察病变情况;另外对肾脏进行HE染色分析(具体操作参见实施例2相关步骤)。同时设置Pkd2f3/f3小鼠作为对照。
结果显示:步骤一得到的Vil-Cre:Pkd2f3/f3小鼠在第4~5月左右死亡,其肾脏、肝脏、胰腺均出现严重的囊肿,而且肾脏的HE染色结果进一步表明肾脏无肾实质,肾功能严重受损,判定Vil-Cre:Pkd2f3/f3小鼠死于肾囊肿导致的肾衰竭,而同窝同龄的Pkd2f3/f3小鼠则表型正常。具体结果如图2所示。
以上结果表明,步骤一得到的Vil-Cre:Pkd2f3/f3小鼠表型与人类ADPKD患者相似,可作为ADPKD动物模型。
实施例2、XAV939在治疗常染色体显性遗传性多囊肾中的应用
本实施例以Vil-Cre:Pkd2f3/f3小鼠作为ADPKD动物模型,研究分析XAV939在治疗常染色体显性遗传性多囊肾中的应用。具体如下:
一、实验方法
1、实验分组及处理
XAV939溶液:将XAV939用DMSO溶解,至其浓度为12mg/mL,后用生理盐水稀释至5mg/ml。
分组及处理:分为治疗组和对照组,每组至少20只Vil-Cre:Pkd2f3/f3小鼠。从小鼠出生后第十天开始,进行连续一周的皮下注射,后改为腹腔注射,每天给药直至小鼠两月龄停药,治疗组每只小鼠按50mg/kg(每kg体重给50mg XAV939)的剂量给药;对照组每只小鼠每天注射等体积的含有等量DMSO的生理盐水。
2、各组小鼠治疗情况分析
(1)HE染色分析两组小鼠的肾囊肿表型
在小鼠两月龄停药后,每组随机选取不少于10只小鼠,处死后,摘除双侧肾脏。在电子天平上精确称重,计算肾脏体重比(g/g),即双侧肾脏重量(g)/体质量(g)。后将双侧肾脏沿着矢状面切开,用10%中性福尔马林溶液固定24小时,后梯度乙醇脱水,然后用石蜡包埋机常规包埋,蜡块待后行切片及HE染色。
A.脱水包埋
具体步骤:①脱水:70%乙醇1h→75%乙醇1h→80%乙醇1h→85%乙醇1h→90%乙醇1h→95%乙醇1h→100%乙醇1h→二甲苯15min×2;②包埋:石蜡包埋机进行包埋。
B.切片
将肾脏蜡块在轮转式切片机上做成3μm厚度的连续肾组织切片,用毛笔轻轻扶起,在温水中将其充分展开,再用多聚赖氨酸处理过的玻片捞起肾组织切片,电热干燥机烤干,然后放于电热恒温鼓风干燥箱里中,70℃恒温烘烤1小时,以使组织切片与玻片紧密粘连,置于盒中备用。
C.HE病理染色
原理:苏木精(hematoxylin)染液为碱性,主要使细胞核内的染色质与胞质内的核糖体着紫蓝色;伊红(eosin)为酸性染料,主要使细胞质和细胞外基质中的成分着红色。
步骤:
①二甲苯脱蜡,后用100%乙醇洗去;
②不同浓度的乙醇依次水化;
③磷酸缓冲液摇床缓洗5分钟;
④苏木精浸提8次;
⑤流水冲洗5分钟;
⑥盐酸酒精浸提8次;
⑦流水冲洗2分钟;
⑧伊红染色10分钟;
⑨不同浓度的乙醇依次脱水;
⑩二甲苯透明,后用中性树胶封片;显微镜观察。
⑾结果显示:细胞浆红色,细胞核蓝紫色。
(2)两组小鼠的肾脏囊肿指数的测定
两组小鼠HE染色的肾脏切片拍照后,图片运行于GNU Image ManipulationProgram。首先将图片转换为灰度图,然后调整图片像素至800×598。将调整后的图片运行添加网格程序,设定每个网格为大小为22×22像素。计算囊肿区域网格数量和肾脏区域总网格数量比例即可得到囊肿指数。
(3)两组小鼠ADPKD相关生化指标的测定
本发明的发明人为了准确反应出治疗组小鼠肾肝功能的改善程度,进一步对两组小鼠血液中尿素氮(BUN)与肌酐(CRE)的含量进行了测定,以此确切反应肾功能的变化情况,反映出囊肿的严重程度。具体操作如下:
在小鼠两月龄时,将实验组及对照组小鼠乙醚麻醉,从下腔静脉抽取小鼠血液,离心后获取上清即为血清。对血清进行化验即可测得肌酐及尿素氮含量。
二、实验结果
1、两组小鼠的肾囊肿表型
HE染色结果如图3所示,从图中可以看出,治疗组较对照组具有更多的肾实质,且治疗组小鼠的肾囊肿表型明显少于对照组。另外,对治疗组与对照组小鼠的肾脏体重比(g/g)测定结果如图4所示,结果显示治疗组的肾脏体重比(g/g)显著小于对照组(p=0.00001),具有统计学意义。
2、两组小鼠的肾脏囊肿指数
两组小鼠的肾脏囊肿指数测定结果如图5所示,治疗组较对照组相比肾脏囊肿指数显著降低(p=0.00002),具有统计学意义。
3、两组小鼠ADPKD相关生化指标的测定
两组小鼠的血液中尿素氮(BUN)与肌酐(CRE)的含量测定结果如图6所示,结果显示,治疗组小鼠的血液中尿素氮(BUN)与肌酐(CRE)的含量较对照组相比,均有下降趋势,治疗组的血液中尿素氮显著小于对照组(p=0.0015),具有统计学意义。
综合本实施例的实验结果,可见XAV939在治疗常染色体显性遗传性多囊肾(ADPKD)中具有一定作用。
Claims (4)
1.XAV939在制备治疗常染色体显性遗传性多囊肾的产品中的应用。
2.XAV939在制备如下任一产品中的应用:
(1)减弱患病机体肾囊肿程度的产品;
(2)降低患病机体肾脏体重比的产品;
(3)降低患病机体的肾脏囊肿指数的产品;
(4)降低患病机体血液中肌酐和/或尿素氮含量的产品。
3.根据权利要求2所述的应用,其特征在于:所述患病机体为具有常染色体显性遗传性多囊肾临床症状的机体。
4.根据权利要求1-3中任一所述的应用,其特征在于:所述产品为药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410409530.1A CN105343096B (zh) | 2014-08-19 | 2014-08-19 | Wnt信号通路抑制剂的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410409530.1A CN105343096B (zh) | 2014-08-19 | 2014-08-19 | Wnt信号通路抑制剂的新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105343096A CN105343096A (zh) | 2016-02-24 |
CN105343096B true CN105343096B (zh) | 2017-12-15 |
Family
ID=55319258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410409530.1A Expired - Fee Related CN105343096B (zh) | 2014-08-19 | 2014-08-19 | Wnt信号通路抑制剂的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105343096B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107349202B (zh) * | 2016-05-09 | 2019-09-06 | 北京仕林伟业生物科技有限公司 | Lgk974在制备治疗多囊肾病的产品中的应用 |
CN111514149B (zh) * | 2020-06-16 | 2021-02-23 | 中国人民解放军空军军医大学 | Xav939在制备治疗孤独症谱系障碍的药物中的应用 |
KR102608039B1 (ko) * | 2020-11-12 | 2023-12-01 | 가톨릭대학교 산학협력단 | 다낭성 신장질환 치료제 및 이의 스크리닝 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140170162A1 (en) * | 2012-12-18 | 2014-06-19 | The Regents Of The University Of California | Preservation of the neuromuscular junction (nmj) after traumatic nerve injury |
-
2014
- 2014-08-19 CN CN201410409530.1A patent/CN105343096B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
"Wnt/β-catenin信号途径与肾脏疾病";闫喆,段惠军;《基础医学与临床》;20101231;第30卷(第12期);1342-1345 * |
"Wnt信号通路与常染色体显性多囊肾病发病关系的研究进展";刘旭 等;《临床和实验医学杂志》;20110131;第10卷(第1期);57-58页 * |
"常染色体显性遗传多囊肾病发病相关信号转导通路的研究进展";周澧 等;《中国病理生理杂志》;20101231;第26卷(第5期);1020-1024、1028页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105343096A (zh) | 2016-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jörs et al. | Lineage fate of ductular reactions in liver injury and carcinogenesis | |
Hunter et al. | The homeobox gene Hhex is essential for proper hepatoblast differentiation and bile duct morphogenesis | |
Dagenais et al. | Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema–distichiasis syndrome | |
Coral-Vazquez et al. | Disruption of the sarcoglycan–sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy | |
Sarmah et al. | Complex cardiac defects after ethanol exposure during discrete cardiogenic events in zebrafish: prevention with folic acid | |
Diep et al. | Development of the zebrafish mesonephros | |
Walentin et al. | A Grhl2-dependent gene network controls trophoblast branching morphogenesis | |
Guetg et al. | Essential amino acid transporter Lat4 (Slc43a2) is required for mouse development | |
Tang et al. | Developmental consequences of abnormal folate transport during murine heart morphogenesis | |
Kroeger Jr et al. | The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development | |
Liang et al. | Elevated glucose induces congenital heart defects by altering the expression of tbx5, tbx20, and has2 in developing zebrafish embryos | |
Griffin et al. | Interplay between FGF, one-eyed pinhead, and T-box transcription factors during zebrafish posterior development | |
CN105664179B (zh) | Phf14基因敲除合并急性肾损伤及损伤后肾纤维化动物模型的建立方法 | |
Abrahamson | Development of kidney glomerular endothelial cells and their role in basement membrane assembly | |
CN105343096B (zh) | Wnt信号通路抑制剂的新用途 | |
Lee et al. | Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV | |
Zhu et al. | Cardiovascular abnormalities in Folr1 knockout mice and folate rescue | |
Sun et al. | Dihydrofolate reductase is required for the development of heart and outflow tract in zebrafish | |
Martini et al. | Exposure to the natural alkaloid Berberine affects cardiovascular system morphogenesis and functionality during zebrafish development | |
Trayer et al. | Assessment of the role of cortisol and corticosteroid receptors in epidermal ionocyte development in the medaka (Oryzias latipes) embryos | |
Fernandez et al. | The coronary arteries of the C57BL/6 mouse strains: implications for comparison with mutant models | |
Gau et al. | Disruption of profilin1 function suppresses developmental and pathological retinal neovascularization | |
Iizuka-Kogo et al. | Requirement of DLG1 for cardiovascular development and tissue elongation during cochlear, enteric, and skeletal development: possible role in convergent extension | |
US9945845B2 (en) | Methods of screening using amphibians | |
Minocha et al. | Segregated hepatocyte proliferation and metabolic states within the regenerating mouse liver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171215 |